Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
95% Confidence Interval
22%
Admission Test
11%
Allied Health
11%
Aminoglycoside-induced Hearing Loss
11%
Aminoglycosides
22%
Antibiotic Duration
11%
Antibiotic Treatment
11%
Antibiotic Use
11%
Antibiotics
33%
Bilateral Deafness
11%
Clinical Costs
22%
Clinical Efficacy
55%
Clinical Pathway
11%
Cochrane
11%
Cost-effectiveness
55%
Cost-effectiveness Analysis
100%
Cost-effectiveness Modeling
11%
Cumulative Index
11%
Diagnostic Assessment
22%
Diagnostic Test Accuracy
11%
Dominant Strategy
11%
Economic Components
11%
Economic Evaluation
11%
Effectiveness Reviews
22%
Embase
11%
Failure Rate
22%
GC Genotype
11%
Gene Drive
100%
Genetic Variants
11%
Gentamicin
11%
Giving Birth
11%
Health Literature
11%
High Risk
11%
Incremental Cost-effectiveness Ratio
11%
Lack of Evidence
11%
Life-years Gained
11%
Low Risk
11%
Maternal Inheritance
11%
MEDLINE
11%
Mitochondrial Genetics
11%
Moderate Risk
11%
MT-RNR1
77%
Neonate
100%
Nursing
11%
Ototoxicity
11%
Outcome Test
11%
Quality Assessment
11%
Quality-adjusted Life Years
11%
RePEc
11%
Review Efficiency
100%
Risk of Bias
22%
Risk of Bias Assessment
11%
Single nucleotide Polymorphism
100%
Standard of Care
11%
Suspected Sepsis
11%
Test Failure
22%
Test Sensitivity
11%
Tomos
11%
Value Assessment
33%
Nursing and Health Professions
Aminoglycoside
33%
Antibiotic Therapy
11%
Antimicrobial Agent
11%
CINAHL
11%
Clinical Effectiveness
55%
Clinical Pathway
11%
Confidence Interval
22%
Cost Effectiveness Analysis
100%
Diagnostic Accuracy
11%
Economic Evaluation
11%
Genetic Variability
11%
Gentamicin
11%
Health Care Quality
11%
Hearing Impairment
22%
Incremental Cost-Effectiveness Ratio
11%
Independent Reviewer
11%
Neonate
100%
Nucleotide
100%
Ototoxicity
11%
Prevalence
11%
Quality Adjusted Life Year
11%
Quality Control
11%
Sepsis
11%
Systematic Review
100%
Biochemistry, Genetics and Molecular Biology
Aminoglycoside
42%
Cinahl
14%
Genetic Divergence
14%
Genotyping
28%
Gentamicin
14%
Hearing
14%
Lifespan
14%
Maternal Inheritance
14%
Mitochondrial Genetics
14%
MT-RNR1
100%
Prevalence
14%
Quality Adjusted Life Year
14%
Single-Nucleotide Polymorphism
100%